Proxy Results (Form 8-K)

On January 23, 2025, Applied DNA Sciences, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, an aggregate of 14,062,557 shares of the Company's common stock ("Common Stock") were present in person or by proxy and entitled to vote, which did not constitute a quorum determined in accordance with the Company's By-Laws, which requires one-third of the Company's issued and outstanding shares of Common Stock. Accordingly, no action was taken with respect to the proposal presented at the Special Meeting, and the Special Meeting was adjourned until February 14, 2025, at 11:00 a.m. in order to permit additional solicitation of stockholders and to allow stockholders additional time to vote on the sole proposal under consideration at the Special Meeting.

As previously reported on its Form 8-K filed on October 31, 2024, the Company closed on such date a registered direct public offering and concurrent private placement (the "Offering") of common stock, series C and D common stock purchase warrants (the "Series Warrants") and placement agent warrants ("Placement Agent Warrants", and, with the Series Warrants, the "Private Placement Warrants"). The Private Placement Warrants will only be exercisable upon receipt of such stockholder approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (the "Warrant Stockholder Approval"). Further, pursuant to the terms of the Securities Purchase Agreement entered into in connection with the Offering, since the Company did not obtain Warrant Stockholder Approval at the Special Meeting, it is obligated to call a subsequent stockholder meeting to seek to obtain Warrant Stockholder Approval.